Stock Forecast

  BiondVax Pharmaceuticals Ltd. ( BVXV) Stock. Should you Buy or Sell?    $ 1.05

0.03 (2.78 %)

BiondVax Pharmaceuticals Ltd. Analysis

Updated on 10-09-2022
Symbol BVXV
Price $1.05
Beta 2.355
Volume Avg. $32.84 thousand
Market Cap $19.58 M
52 Week Range $0.981 - $3.49

BiondVax Pharmaceuticals Ltd. opened the day at $1.05 which is +'2.78 % on yesterday's close. BiondVax Pharmaceuticals Ltd. has a 52 week high of $3.49 and 52 week low of $0.981, which is a difference of $2.509. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $19.58 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy BiondVax Pharmaceuticals Ltd. for $19.58 M, it would take 15 years to get your money back. BiondVax Pharmaceuticals Ltd. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


BiondVax Pharmaceuticals Ltd. Stock Forecast - Is BiondVax Pharmaceuticals Ltd. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreStrong Buy
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value

PE Ratio -1.549
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing BiondVax Pharmaceuticals Ltd.

Price Book Value Ratio 14.585 Price To Book Ratio 14.585
Price To Sales Ratio 0.000 Price Earnings Ratio -1.549

How liquid is BiondVax Pharmaceuticals Ltd.

Current Ratio 1.706
Quick Ratio 1.706


Debt Ratio 0.948 Debt Equity Ratio 18.152
Long Term Debt To Capitalization 0.928 Total Debt To Capitalization 0.945

Latest news about BiondVax Pharmaceuticals Ltd.

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference

JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

Date : 08/09/2022

BiondVax to Present at this week's Biomed Israel Conference

JERUSALEM  , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.

Date : 09/05/2022

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

Date : 04/04/2022

Why Is BiondVax (BVXV) Stock Up Today?

BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.

Date : 24/03/2022

Here's Why Biondvax Pharmaceuticals Shares Are Rising

Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid.

Date : 24/03/2022

About BiondVax Pharmaceuticals Ltd.

CEO : Dr. Ron Babecoff
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Capital Market

Description :

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

My Newsletter

Sign Up For Updates & Newsletters